BBC: Virtus LifeSci Biotech Clinical Trials ETF - MutualFunds.com
Continue to site >
Trending ETFs

Welcome to MutualFunds.com

Please help us personalize your experience and select the one that best describes you.

Your personalized experience is almost ready.

Join other Individual Investors receiving FREE personalized market updates and research. Join other Institutional Investors receiving FREE personalized market updates and research. Join other Financial Advisors receiving FREE personalized market updates and research.
Not interested

Thank you!

Check your email and confirm your subscription to complete your personalized experience.

Thank you for your submission

We hope you enjoy your experience

You have successfully subscribed to Advisor Access. Thank you!
Help us personalize your experience.
Which type of investor describes you best?
Help us personalize your experience.
What is your AUM?
Knowing your investable assets will help us build and prioritize features that will suit your investment needs.

Congratulations on personalizing your experience.

Email is verified. Thank you!

Rating
Sector Rating
Recommendation *
Avoid
Neutral
Fair
Quality
Rating Breakdown
Avg.
Relative Strength
The relative strength of a dividend stock indicates whether the stock is uptrending or not. The major determining factor in this rating is whether the stock is trading close to its 52-week-high.
Overall Yield Attractiveness
If a stock’s yield is above or near the market average then it will be rated higher within this parameter. High dividend yields (usually over 10%) should be considered extremely risky, while low dividend yields (1% or less) are simply not very beneficial to long-term investors.
Dividend Reliability
A stock’s dividend reliability is determined by a healthy payout ratio that is higher than other stocks. A company that pays out close to half its earnings as dividends and retains the other half of earnings has ample room to grow its business and pay out more dividends in the future.
Dividend Uptrend
A stock’s Dividend Uptrend rating is dependent on the company’s price-to-earnings (P/E) ratio to evaluate whether or not a stock’s dividend is likely to trend upward. If a stock is valued near, or slightly below the market average, research has shown that the market expects the stock’s dividend to increase.
Earnings Growth
A stock’s Earnings Growth rating evaluates a company’s expected EPS for the current financial year and compares it to next financial year’s expected EPS. Stocks with single-digit growth estimates will have a higher rating than others, as our research has shown that well-established dividend-paying companies have modest earnings growth estimates.
Upgrade to Premium to get unlimited access to Ratings, Recommendations, Payout Estimates, and more.

Virtus LifeSci Biotech Clinical Trls ETF

BBC - Snapshot

Vitals

  • YTD Return 8.5%
  • 3 Yr Annualized Return 20.6%
  • 5 Yr Annualized Return 11.6%
  • Net Assets $47.3 M
  • Holdings in Top 10 8.8%

52 WEEK LOW AND HIGH

N/A
N/A
N/A

Expenses

OPERATING RELATED FEES

  • Expense Ratio 0.79%

SALES FEES

  • Front Load N/A
  • Deferred Load N/A

BROKERAGE FEES

  • Turnover 81.00%

TRADING FEES

  • Max Redemption Fee N/A

Min Investment

  • Standard (Taxable) N/A
  • IRA N/A

Fund Classification

Compare BBC to Popular Health Care Sector Equity Funds and ETFs

Overview

Income Profile

Income Risk

Returns Profile

Allocations

Expenses

About

Vanguard Health Care Fund

Fund

$223.19

+0.14%

$49.03 B

0.85%

$1.89

3.47%

-

Health Care Select Sector SPDR® Fund

XLV | ETF

$116.97

+0.31%

$25.69 B

1.45%

$1.69

3.11%

-

T. Rowe Price Health Sciences Fund

Fund

$104.19

-0.16%

$17.43 B

-

$0.00

5.40%

-

Vanguard Health Care Index Fund

Fund

$116.28

+0.15%

$15.36 B

1.17%

$1.36

3.90%

-

Vanguard Health Care Index Fund

VHT | ETF

$232.30

+0.02%

$15.36 B

1.17%

$2.71

3.83%

-

BBC - Profile

Distributions

  • YTD Total Return 8.5%
  • 3 Yr Annualized Total Return 20.6%
  • 5 Yr Annualized Total Return 11.6%
  • Capital Gain Distribution Frequency N/A
  • Net Income Ratio -0.41%
DIVIDENDS
  • Dividend Yield 0.0%
  • Dividend Distribution Frequency Annually

Fund Details

  • Legal Name
    Virtus LifeSci Biotech Clinical Trials ETF
  • Fund Family Name
    Virtus
  • Inception Date
    Dec 16, 2014
  • Shares Outstanding
    950004
  • Share Class
    N/A
  • Currency
    USD
  • Domiciled Country
    United States
  • Manager
    Matthew Brown

Fund Description

Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering ("lead drug") that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval.

BBC - Performance

Return Ranking - Trailing

Period BBC Return Category Return Low Category Return High Rank in Category (%)
YTD 8.5% 1.3% 15.8% 8.14%
1 Yr 30.8% 3.0% 180.5% 27.61%
3 Yr 20.6%* 3.8% 59.5% 9.09%
5 Yr 11.6%* 1.0% 36.9% 50.00%
10 Yr N/A* 9.8% 21.3% N/A

* Annualized

Return Ranking - Calendar

Period BBC Return Category Return Low Category Return High Rank in Category (%)
2020 30.3% -13.6% 178.2% 14.29%
2019 63.8% 3.8% 63.8% 0.69%
2018 -18.3% -49.7% 21.5% 89.78%
2017 54.4% -59.8% 54.4% 0.74%
2016 -36.6% -36.6% 11.6% 100.00%

Total Return Ranking - Trailing

Period BBC Return Category Return Low Category Return High Rank in Category (%)
YTD 8.5% 1.3% 15.8% 8.14%
1 Yr 30.8% -2.3% 180.5% 23.93%
3 Yr 20.6%* 2.4% 59.5% 9.09%
5 Yr 11.6%* 1.0% 36.9% 47.14%
10 Yr N/A* 9.8% 21.3% N/A

* Annualized

Total Return Ranking - Calendar

Period BBC Return Category Return Low Category Return High Rank in Category (%)
2020 30.3% -13.6% 178.2% 14.29%
2019 63.8% 3.8% 63.8% 0.69%
2018 -18.3% -25.3% 22.2% 91.24%
2017 54.4% -10.8% 54.4% 0.74%
2016 -36.6% -36.6% 11.6% 100.00%

BBC - Holdings

Concentration Analysis

BBC Category Low Category High BBC % Rank
Net Assets 47.3 M 6.3 M 49 B 81.98%
Number of Holdings 165 24 459 9.30%
Net Assets in Top 10 4.16 M 1.2 M 19.6 B 91.28%
Weighting of Top 10 8.80% 8.8% 76.9% 100.00%

Top 10 Holdings

  1. Novavax Inc 2.04%
  2. Sorrento Therapeutics Inc 1.91%
  3. MyoKardia Inc 1.88%
  4. BioNTech SE ADR 1.71%
  5. Atara Biotherapeutics Inc 1.65%
  6. Denali Therapeutics Inc 1.64%
  7. Moderna Inc 1.64%
  8. Kodiak Sciences Inc 1.57%
  9. Mirati Therapeutics Inc 1.54%
  10. Kura Oncology Inc 1.48%

Asset Allocation

Weighting Return Low Return High BBC % Rank
Stocks 		98.44% 77.04% 104.32% 50.00%
Cash 		1.56% -0.10% 12.53% 38.95%
Preferred Stocks 		0.00% 0.00% 5.23% 49.42%
Other 		0.00% -27.80% 10.43% 55.81%
Convertible Bonds 		0.00% 0.00% 0.06% 41.28%
Bonds 		0.00% 0.00% 19.34% 45.93%

Stock Sector Breakdown

Weighting Return Low Return High BBC % Rank
Healthcare 		98.79% 61.64% 100.00% 68.02%
Basic Materials 		1.21% 0.00% 3.30% 6.40%
Utilities 		0.00% 0.00% 0.00% 40.70%
Technology 		0.00% 0.00% 15.86% 50.58%
Real Estate 		0.00% 0.00% 5.95% 46.51%
Industrials 		0.00% 0.00% 5.94% 47.67%
Financial Services 		0.00% 0.00% 4.10% 63.95%
Energy 		0.00% 0.00% 0.03% 41.28%
Communication Services 		0.00% 0.00% 4.69% 43.60%
Consumer Defense 		0.00% 0.00% 33.59% 45.93%
Consumer Cyclical 		0.00% 0.00% 1.19% 45.35%

Stock Geographic Breakdown

Weighting Return Low Return High BBC % Rank
US 		87.12% 56.44% 100.00% 30.81%
Non US 		11.32% 0.00% 41.69% 63.37%

BBC - Expenses

Operational Fees

BBC Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 0.79% 0.08% 25.14% 65.27%
Management Fee 0.79% 0.00% 1.25% 66.86%
12b-1 Fee N/A 0.00% 1.00% N/A
Administrative Fee N/A 0.03% 0.40% N/A

Sales Fees

BBC Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load N/A 3.50% 5.75% N/A
Deferred Load N/A 1.00% 5.00% N/A

Trading Fees

BBC Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A 1.00% 2.00% N/A

Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

BBC Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover 81.00% 0.70% 252.00% 85.37%

BBC - Distributions

Dividend Yield Analysis

BBC Category Low Category High BBC % Rank
Dividend Yield 0.00% 0.00% 1.05% 50.00%

Dividend Distribution Analysis

BBC Category Low Category High Category Mod
Dividend Distribution Frequency Annually Annually Monthly Quarterly

Net Income Ratio Analysis

BBC Category Low Category High BBC % Rank
Net Income Ratio -0.41% -2.53% 1.74% 76.79%

Capital Gain Distribution Analysis

BBC Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Annually Annually

Dividend Payout History

View More +

BBC - Fund Manager Analysis

Managers

Matthew Brown

Start Date

Tenure

Tenure Rank

Aug 14, 2017

3.38

3.4%

Matthew Brown serves as Portfolio Manager at Virtus ETF Advisers LL. Mr. Brown is also executive managing director and chief operating officer at Virtus ETF Solutions LLC (“VES”) since 2012. Before founding VES in 2012, he served as director of operations for Factor Advisors from 2010 to 2012. In 2009, Mr. Brown co-founded ETP Resources, a consulting and data services business that continues to grow and serve the ETF industry. From 2008 to 2009, he headed U.S. operations and served as chief compliance officer for U.K.-based issuer SPA/London & Capital. Mr. Brown earned a B.A. in Economics from Boston College.

Seth Kadushin

Start Date

Tenure

Tenure Rank

Aug 14, 2017

3.38

3.4%

Seth Kadushin serves as Portfolio Manager at Virtus ETF Advisers LLC. Mr. Kadushin has also served as director of capital markets at Virtus ETF Solutions LLC (“VES”) since 2013. Prior to joining VES, Mr. Kadushin worked at Euromoney Institutional Investor, Plc where he developed large scale investment management programs focusing on Exchange Traded Instruments and Alternate Investment Strategies. From 2011 through 2012 Mr. Kadushin worked at Wedbush Securities as an Options Desk Strategist. Mr. Kadushin worked at RBS Securities as Head Program Trader from 2009 through 2011. Prior to 2009, Mr. Kadushin held senior level positions at Lehman Brothers and Bear Sterns (J.P. Morgan), where he was a member of the firm’s Cross Asset Policy Committee charged with instituting their equity trading division’s guidelines. Mr. Kadushin holds a BBA in Finance from Emory University. He achieved his Master’s in Business from Fordham University with a concentration in Information Systems.

Tenure Analysis

Category Low Category High Category Average Category Mode
0.04 23.31 7.3 20.68

Advertisement

×

Wait! Do you know all the important aspects of mutual funds?

×

Free Advisor Access newsletter emailed to you.

Receive free and exclusive email updates for financial advisors about best performers, news, CE accredited webcasts and more.

Sign up for Advisor Access

Receive email updates about best performers, news, CE accredited webcasts and more.

Disclaimer: By registering, you agree to share your data with MutualFunds.com and opt-in to receiving occasional communications about projects and events. The contents of this form are subject to the MutualFunds.com Privacy Policy. You can unsubscribe at any time.